FDA Approves Biogen Psoriasis Drug
CAMBRIDGE, Mass. (AP) _ Biogen, Inc. said Friday that the Food and Drug Administration had approved its drug Amevive, used to treat moderate and severe cases of the skin disorder psoriasis.
Psoriasis causes skin cells to multiply abnormally fast and pile up in scaly plaques. Many patients respond to treatment from topical ointments, but Biogen said more than one million require ultraviolet or ``systematic therapies,″ like Amevive, which attack the cause of the disease.
An FDA advisory panel recommended Amevive’s approval in May.
Amevive is the second drug on the market for Cambridge-based Biogen. Its multiple sclerosis drug Avonex is facing new competition.